Data through Q2 2014. Source: Johnson & Johnson.
Make no mistake about it: J&Js pharmaceutical segment is where its juicy margins and profit growth are generated. Since 2009, and through mid-2014, Johnson & Johnson has introduced 14 new molecular entity drugs to market that resulted in $12.5 billion in cumulative sales. These include Imbruvica, a blood cancer drug with remarkable efficacy that it co-developed with Pharmacyclics , and Invokana, a new type of diabetes therapy known as an SGLT2 inhibitor that works in the kidneys to block glucose absorption and allows type 2 diabetics to rid excess glucose through their urine.
With plenty of high-growth therapeutic fields represented in its product portfolio and a 52-year streak of dividend increases, this is the shining star of all pharmaceuticals that deserves your attention.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism, The Economist is calling it "transformative," but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article 10 Largest Companies by Market Cap in Pharmaceuticals originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns shares of and recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
